Back

Cardiovascular and renal outcomes of Semaglutide in patients with Type 2 Diabetes Mellitus with established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: A Meta-Analysis

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy and cardiovascular outcomes Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Francis Paolo Lumancas

PERPETUAL SUCCOUR HOSPITAL OF CEBU INC, Cebu City (Philippines)

5 More presentations in this session

Presentation thumbnail
B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease
Doctor T. Nagahiro (Yokohama, JP)
Abstract
Presentation thumbnail
Impact of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a meta-analysis of randomized controlled trials
Doctor C. Cotticelli (Naples, IT)
Abstract
Presentation thumbnail
Effects of luseogliflozin on sympathetic nerve activity:a dual assessment using iodine-123-metaiodobenzylguanidine and muscle sympathetic nerve activity
Mr T. Hirai (Kanazawa, JP)
Abstract
Presentation thumbnail
Comparative cardiovascular efficacy of individual GLP-1 receptor agonists and tirzepatide: a Bayesian network meta-analysis of 13 cardiovascular outcome trials
Ms Y. Srivastava (IN)
Abstract
Presentation thumbnail
Regression of microalbuminuria predicts cardiovascular risk reduction with GLP-1 receptor agonist therapy
Doctor I. Figueroa Baez (San Juan, PR)
Abstract

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025
thumbnail
Congress Presentation
Renal and cardiovascular benefits of treatment with angiotensin receptor blockers in patients with hypertension and chronic kidney disease: A systematic review and meta-analysis
1 September 2019
thumbnail
Congress Presentation
Efficacy of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease
29 August 2025
thumbnail
Congress Presentation
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources